Epigallocatechin-3-Gallate

Phase 2Small molecule

Epigallocatechin-3-Gallate is one of 67 small molecule programs targeting Pulmonary Fibrosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pulmonary FibrosisActive, not recruiting

AmyloidosisActive, not recruiting

FrailtySuspended

Pulmonary FibrosisPhase 1

Active, not recruiting

AmyloidosisPhase 2

Active, not recruiting

FrailtyPhase 2

Suspended

Competition

Competitive Landscape

76 competitors in Amyloidosis

#DrugCompanyPhaseTrials

Ninlaro

Takeda

Phase 3

2 2

Thalomid

Bristol-Myers Squibb

Phase 3

2 3

Cytoxan

BBaxter Healthcare Corporation

Phase 3

8 4

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

5 5

Decadron

AAspen Global Incorporated

Phase 2

27 6

Darzalex

Johnson & Johnson

Phase 2

6 7

Onpattro

Alnylam Pharmaceuticals

Phase 2

5 8

Venclexta

AbbVie

Phase 2

4 9

Velcade

SShilpa Grover, MD, MPH

Alkeran

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Amyloidosis1 trial

A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL)

Completed·FFlorian Michel·Phase 2·NCT02015312·38 enrolled

Pulmonary Fibrosis1 trial

Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.

Completed·HHal Chapman·Phase 1·NCT03928847·35 enrolled

Prevention1 trial

EGCG for the Prevention and Treatment of TIPN

Recruiting·HHan Xi Zhao·Phase 1/2·NCT06524609·36 enrolled

Frailty1 trial

A Phase 2 Randomized Controlled Trial of Epigallocatechin-3-Gallate (EGCG) on Frailty and Inflammation in Older Survivors of Cancer

Suspended·UUniversity of Rochester·Phase 2·NCT06068543·118 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Epigallocatechin-3-Gallate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Epigallocatechin-3-Gallate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Epigallocatechin-3-Gallate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Rochester company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Rochester

Epigallocatechin-3-Gallate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Amyloidosis1 trial

Pulmonary Fibrosis1 trial

Prevention1 trial

Frailty1 trial

References

Drug Info

Quick Facts

Related News